These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32919519)

  • 1. Foot ulcers in systemic sclerosis escape surgical amputation.
    Abignano G; Mennillo GA; Lettieri G
    Lancet; 2020 Sep; 396(10253):e29. PubMed ID: 32919519
    [No Abstract]   [Full Text] [Related]  

  • 2. Possible role of iloprost (stable analog of PG12) in promoting neoangiogenesis in systemic sclerosis.
    Faggioli P; Giani L; Mazzone A
    Clin Exp Rheumatol; 2006; 24(2):220-1. PubMed ID: 16762173
    [No Abstract]   [Full Text] [Related]  

  • 3. Case series of recalcitrant livedoid vasculopathy treated with rivaroxaban.
    Lee JM; Kim IH
    Clin Exp Dermatol; 2016 Jul; 41(5):559-61. PubMed ID: 26993107
    [No Abstract]   [Full Text] [Related]  

  • 4. Raynaud, digital ulcers and calcinosis in scleroderma.
    Nitsche A
    Reumatol Clin; 2012; 8(5):270-7. PubMed ID: 22835924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Digital ulcers in systemic sclerosis].
    Guillevin L
    Presse Med; 2008 Apr; 37(4 Pt 2):735-6. PubMed ID: 18258409
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
    Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
    Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Iloprost for the treatment of systemic sclerosis].
    Hachulla E; Launay D; Hatron PY
    Presse Med; 2008 May; 37(5 Pt 2):831-9. PubMed ID: 18035518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous laser doppler flux distribution in ischemic ulcers and the effect of prostanoids: a crossover study comparing the acute action of prostaglandin E1 and iloprost vs saline.
    Gschwandtner ME; Koppensteiner R; Maca T; Minar E; Schneider B; Schnürer G; Ehringer H
    Microvasc Res; 1996 Jan; 51(1):29-38. PubMed ID: 8812752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 37-year-old man with painful foot.
    Geske JB; Calvin AD; McDonald FS
    Mayo Clin Proc; 2008 Jul; 83(7):821-4. PubMed ID: 18613988
    [No Abstract]   [Full Text] [Related]  

  • 10. [The treatment of skin ulcers in patients with systemic sclerosis].
    Fiori G; Amanzi L; Moggi Pignone A; Braschi F; Matucci-Cerinic M
    Reumatismo; 2004; 56(4):225-34. PubMed ID: 15643477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of oxycodone/naloxone in the management of chronic pain in patients with systemic sclerosis with recurrent digital ulcers: two case reports.
    Ughi N; Crotti C; Ingegnoli F
    Clin Interv Aging; 2016; 11():307-11. PubMed ID: 27042030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
    Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
    Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is iloprost effective in secondary Raynaud's phenomenon?
    Lustig N; Rada G
    Medwave; 2015 Mar; 15(2):e6082. PubMed ID: 25826330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What are biofilms? Evaluation and management in open skin wounds.
    Boutli-Kasapidou F; Delli F; Avgoustinaki N; Lambrou N; Tsatsos M; Karakatsanis G
    J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):743-5. PubMed ID: 16836513
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach.
    Catapano-Minotti G; Corsonello A; Guadalupi G; Spani R; Antonelli-Incalzi R
    Intern Med; 2008; 47(6):511-3. PubMed ID: 18344637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iloprost treatment in pediatric patients with complicated Raynaud's phenomenon.
    Cekic S; Kilic SS
    Lupus; 2016 Apr; 25(5):558-60. PubMed ID: 26692039
    [No Abstract]   [Full Text] [Related]  

  • 17. Axonal degeneration in systemic sclerosis can be reverted by factors improving tissue oxygenation.
    Provitera V; Nolano M; Pappone N; Lubrano E; Stancanelli A; Lanzillo B; Santoro L
    Rheumatology (Oxford); 2007 Nov; 46(11):1739-41. PubMed ID: 17938133
    [No Abstract]   [Full Text] [Related]  

  • 18. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
    Cochrane Database Syst Rev; 2000; 1998(2):CD000953. PubMed ID: 10796395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study.
    Negrini S; Magnani O; Matucci-Cerinic M; Carignola R; Data V; Montabone E; Santaniello A; Adorni G; Murdaca G; Puppo F; Indiveri F; Della Rossa A; D'Ascanio A; Barsotti S; Giuggioli D; Ferri C; Lumetti F; Bosello SL; Canestrari G; Bellando Randone S; Bruni C; Guiducci S; Battaglia E; De Andres MI; Russo AA; Beretta L
    Clin Exp Med; 2019 Aug; 19(3):357-366. PubMed ID: 30989453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine production in scleroderma patients: effects of therapy with either iloprost or nifedipine.
    Della Bella S; Molteni M; Mascagni B; Zulian C; Compasso S; Scorza R
    Clin Exp Rheumatol; 1997; 15(2):135-41. PubMed ID: 9196864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.